Back to the directory
Coral Genomics
New clinical tests for managing autoimmune treatments.
- Founded
- 2018
- Status
- Acquired
- Stage
- Early
- Team size
- 5
- Location
- San Francisco, CA, USA
- Category
- Biotech & Drug Discovery
- Sector
- Drug Discovery and Delivery
About Coral Genomics
Coral integrates molecular, functional, and clinical factors to create new clinical laboratory tests that predict optimal treatments for autoimmune diseases. We have also identified a unique subpopulation of patients who do not respond to current therapies and are working towards addressing this unmet medical need.
Genomics
Clinical trials
1 registered trial with this company as lead sponsor, 2020.
- Status
- Terminated (1)
- Conditions
- Ulcerative Colitis, Crohn's Disease, Psoriasis, Rheumatoid Arthritis
Source: ClinicalTrials.gov.
Federal research funding
4 NIH awards totalling $2,953,881, FY2019 to FY2021.
- Multiplexing methods to reduce sequencing costs
- In Vitro Toxicity Testing at Massive Scale in Diverse Primary Human Cells
- Multiplexing methods to reduce sequencing costs.
Source: NIH RePORTER.
Company data compiled and maintained by Healthcare Discovery.
